Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.